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ABSTRACT
Pirfenidone is currently the only approved
therapy for idiopathic pulmonary fibrosis,
following studies demonstrating that treatment
reduces the decline in lung function and
improves progression-free survival. Although
generally well tolerated, a minority of patients
discontinue therapy due to gastrointestinal and
skin-related adverse events (AEs). This review
summarizes recommendations based on existing
guidelines, research evidence, and consensus
opinions of expert authors, with the aim of
providing practicing physicians with the specific
clinical information needed to educate the
patient and better manage pirfenidone-related
AEs with continued pirfenidone treatment. The
main recommendations to help prevent and/or
mitigate gastrointestinal and skin-related AEs
include taking pirfenidone during (or after) a
meal, avoiding sun exposure, wearing protective
clothing, and applying a broad-spectrum
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sunscreen with high ultraviolet (UV) A and UVB
protection. These measures can help optimize AE
management, which is key to maintaining
patients on an optimal treatment dose.
Keywords: Adverse event management; Expert
opinion; Gastrointestinal events; Idiopathic
pulmonary fibrosis; Photosensitivity;
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events
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a rare,
progressive, irreversible and ultimately fatal
chronic lung disease. Studies in Europe suggest
that prevalence ranges from 1 to 23 cases per
100,000 persons [1–6]. Prevalence and
incidence rates increase with age, are higher
among males and appear to be on the increase
in recent years [7]. Prognosis is poor, with a
median survival time of 2–5 years [8–12].
Pirfenidone is currently the only approved
drug for the treatment of adult patients with
mild to moderate IPF [13]. It is licensed for use
in the European Union and Canada (under the
trade name Esbriet, InterMune UK Ltd.,
London, UK) and in Japan, India, South Korea,
and China. Data from Phase III, randomized,
double-blind, placebo-controlled trials
demonstrate that pirfenidone reduces the
decline in lung function and improves
progression-free survival time [14, 15]. In these
studies, treatment with pirfenidone was safe
and generally well tolerated; the most
commonly reported treatment-emergent
adverse events (AEs) were gastrointestinal (GI)
and skin-related. These were generally mild to
moderate in severity and rarely resulted in
treatment discontinuation.
While pirfenidone is generally well tolerated,
a minority of patients discontinue treatment
due to AEs. In light of the vital importance of
treatment compliance in patients with IPF, a
clinical advisory board comprising experts in
pulmonology (E. Bendstrup, U. Costabel, V.
Cottin, J. J. J. Egan, M. Kreuter, T. Maher, M.
Molina-Molina, C. Vancheri), gastroenterology
(P. Dewint, P.M. Hellstro¨m, A. Sarafidis), and
dermatology (J. Ferguson, R. Groves, K.
Nordlind), and supported by a grant from
InterMune International AG, was convened in
Basel, Switzerland, to discuss the prevention
and management of pirfenidone-related GI and
skin-related AEs.
This review summarizes the
recommendations that have been generated
based on existing guidelines, a review of current
research evidence, and consensus opinions of
this international group of experts. The
recommendations may be adapted for use in
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different countries or regions according to the
availability of treatment modalities and treating
physicians’ judgment. The experts’ meeting
aimed to provide practicing physicians with
specific clinical information needed to best
educate the patient and manage AEs with
continued pirfenidone treatment. These
recommendations will be revised regularly
following systematic review of new research
evidence as it becomes available.
The analysis in this article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
OVERVIEW OF PIRFENIDONE
Pirfenidone is an orally active, synthetic small
molecule that inhibits the synthesis of
transforming growth factor-b and tumor
necrosis factor-a in preclinical models, both of
which are cytokines known to play an active
role in fibrosis and inflammation [16–21].
Following oral administration with food to
improve tolerability, pirfenidone is slowly
absorbed and reaches peak concentrations
after approximately 4 h [22]. The mean
apparent terminal elimination half-life is
approximately 2.4 h [23].
Efficacy Profile
The clinical efficacy and safety of pirfenidone
has been evaluated in four randomized,
double-blind, placebo-controlled trials,
including a Phase II Japanese study, a Phase III
Japanese study, and two multinational Phase III
trials [the CAPACITY studies PIPF004
(Clinicaltrials.gov #NCT00287716) and PIPF006
(Clinicaltrials.gov #NCT00287729)] conducted
in Europe, North America and Australia [14, 15,
24]. Data from the three Phase III, randomized,
double-blind, placebo-controlled studies
demonstrate that pirfenidone reduces the
decline in lung function and improves
progression-free survival [14, 15]. The two
Phase III CAPACITY studies of pirfenidone in
patients with IPF were designed similarly in order
to enable pooling of data [25]. Analyses of pooled
data from both trials enabled precise estimates of
the magnitude of the treatment effect [25].
Results from the pooled analysis of categorical
FVC change showed that pirfenidone reduced
the proportion of patients experiencing at least a
10% decline by 30% compared with placebo [15].
Additionally, numerically fewer overall deaths
occurred in the pirfenidone versus placebo group
[19 (6%) vs. 29 (8%); P = 0.141]. Significant and
clinically meaningful treatment effects were
observed across multiple outcomes in the
CAPACITY studies (Fig. 1a) [26]. At Week 72,
pirfenidone also reduced the proportion of
patients with a 50 m or greater decrement in
6-min walk distance (31% relative reduction vs.
placebo) and reduced the risk of death or disease
progression (26% reduction vs. placebo,
P = 0.025) [15].
Safety Profile
The clinical safety profile of pirfenidone in
patients with IPF has been demonstrated
in large randomized, double-blind,
placebo-controlled trials [14, 15, 24], as well as
in an ongoing long-term open-label extension
trial [RECAP (Clinicaltrials.gov #NCT00662038)].
Pirfenidone’s safety profile has been evaluated in
a well-defined cohort of 789 patients exposed to
treatment for up to 8 years (long-term safety
pooling) [27]. In the CAPACITY studies,
treatment with pirfenidone was generally well
tolerated. Treatment discontinuation due to AEs
was more common among pirfenidone
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2,403 mg/day patients (15%) compared with
placebo patients (9%); relative risk of 1.85 (95%
CI 1.28–2.67, P = 0.001) [15, 28].
Based on observations from the Japanese
trials [14, 24], proactive protocol-defined
strategies including dose modification
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guidelines were implemented in the CAPACITY
studies to minimize the incidence and severity
of selected AEs (such as GI and skin-related AEs)
and encourage patients to continue treatment.
The most common AE leading to treatment
discontinuation in both groups in the
CAPACITY studies was IPF (3% in each group).
Other AEs leading to treatment discontinuation
in at least 1% of pirfenidone-treated patients
were rash and nausea.
The relatively low incidence of treatment
discontinuation due to GI and skin-related AEs
in the CAPACITY studies, compared with
the Japanese studies, supports the use of
protocol-defined strategies for proactively
managing these events. However, GI and
skin-related AEs remained the most
commonly reported AEs in the CAPACITY
studies. Gastrointestinal events of nausea,
diarrhea, dyspepsia and vomiting were
reported in 36%, 29%, 19% and 14% of
pirfenidone-treated patients versus 17%, 19%,
7%, and 4% of placebo-treated patients,
respectively [15] (InterMune data on file).
Skin-related AEs of rash and photosensitivity
were reported in 32% and 12% of
pirfenidone-treated patients versus 12% and
2% of placebo-treated patients, respectively
[15]. These events were generally mild to
moderate in intensity, reversible, and with
minimal clinical consequence (Tables 1, 2).
Gastrointestinal and skin-related AEs led to
treatment discontinuation in six (1.7%) and
eight (2.3%) pirfenidone-treated patients,
respectively. The long-term safety pooling
including 789 patients showed that GI and
skin-related AEs have a tendency to occur early
in the course of treatment and decrease over
time [27].
Elevations in alanine aminotransferase (ALT)
and aspartate aminotransferase (AST) of more
than three times the upper limit of normal
occurred more frequently in the pooled
pirfenidone group than in the pooled placebo
group [14/345 (4%) vs. 2/347 (\1%),
respectively] in the CAPACITY studies [15].
Rarely, these have been associated with
concomitant elevations in bilirubin. Liver
function tests (ALT, AST, and bilirubin) should
be conducted prior to the initiation of treatment
with pirfenidone, and subsequently at monthly
intervals for the first 6 months and then every
3 months thereafter [23].
Gastrointestinal Adverse Events
Gastrointestinal AEs occurred at higher
frequencies in patients treated with
pirfenidone 2,403 mg/day compared with
placebo in the CAPACITY studies (Table 1).
Importantly, there were no GI-related
treatment-emergent serious AEs or
hospitalizations among patients treated with
pirfenidone. Overall, five (1.4%) and one (0.3%)
pirfenidone patients discontinued therapy due
Fig. 1 Clinical and preclinical pirfenidone data.
a Consistent magnitude of treatment effect with
pirfenidone across multiple clinically meaningful outcomes
in patients with IPF [15]. Bars represent the magnitude of
treatment effect, reported as relative difference between the
pirfenidone and placebo groups. *From the pooled analysis
of the CAPACITY studies at 72 weeks. Progression-free
survival was defined as time to confirmed C10% decline in
percentage predicted FVC, C15% decline in percentage
predicted DLco or death. Deaths were not adjudicated and
studies were not powered to evaluate mortality. b The
incidence of pirfenidone-related skin rashes in patients
with IPF was higher in the early summer months of the
CAPACITY studies 004 and 006. Adapted from
European Medicine Agency. Pirfenidone CHMP
assessment report [38]. c Pirfenidone absorbs light in the
ultraviolet spectrum. Adapted from Seto et al. [30].
6MWD 6-min walk distance, DLco carbon monoxide
diffusing capacity, e molar absorptivity coefficient, FVC
forced vital capacity, IPF idiopathic pulmonary fibrosis,
kmax wavelength of the most intense ultraviolet absorption,
PBO placebo, PEY patient-exposed years, PFD
pirfenidone, PFS progression-free survival, UV ultraviolet
b
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to nausea and vomiting, respectively, and two
(0.6%) discontinued due to diarrhea.
Gastrointestinal AEs were mostly transient in
nature, although dyspepsia was present for a
median duration of 168 days [15]. While
GI-related AEs were generally mild to moderate
and transient, the frequency of such events
suggests the need for proactive management.
Animal studies have shown that pirfenidone
reduces the rate of gastric emptying and small
intestinal transit [29]. These effects in rats were
ameliorated by co-administration of prokinetic
agents. Concomitant administration of
mosapride at 3 and 10 mg/kg resulted in
significant amelioration in the decrease in
gastric emptying rate induced by 100 mg/kg
pirfenidone, while 1 mg/kg mosapride or greater
ameliorated the decreased small intestinal
transit rate [29]. Furthermore, GI effects in
animals were observed following subcutaneous
injection, indicating that systemic exposure is
required for pirfenidone’s gastric motility effects
(InterMune data on file). The effect of food
on the pharmacokinetics of pirfenidone
has previously been examined in healthy
adult subjects. It was demonstrated that
co-administration with food decreased the peak
concentration of pirfenidone (area under the
curve was unchanged), with data also suggesting
that food intake reduces the risk of GI-related AEs,
thereby improving overall tolerability [22].
Skin Reactions
Skin-related AEs in the context of pirfenidone
therapy can manifest as an erythematous (with/
without edema) or as a phototoxic burn-like
skin rash, occurring on sun-exposed body areas.
This differs from an allergic type of eruption,
which will usually affect all parts of the skin,
including areas not exposed to sunlight. In the
Table 2 Skin-related adverse events in the CAPACITY studies
Rash Photosensitivity reaction
Pirfenidone 2,403 mg/day
(N5 345)
Placebo
(N5 347)
Pirfenidone 2,403 mg/day
(N5 345)
Placebo
(N5 347)
Grade 3 or 4 TEAEs, n (%) 2 (0.6) 0 (0.0) 3 (0.9) 1 (0.3)
TE SAEs, n (%) 1 (0.3)a 0 (0.0) 1 (0.3) 0 (0.0)
Deaths (n) 0 0 0 0
Hospitalization, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Discontinuation, n (%) 5 (1.4) 0 (0.0) 3 (0.9) 1 (0.3)
Dose modification, n (%) 42 (12.2) 5 (1.5) 19 (5.5) 1 (0.3)
Events (n) 159 52 60 8
Median duration (days) 38 31 88 60
Resolved, n (%) 132 (83) 46 (88) 47 (78) 6 (75)
No formal definition of rash versus photosensitivity reaction was employed; the distinction was made by the physician based
on his/her clinical observation
TEAE treatment-emergent adverse event, TE SAE treatment-emergent severe adverse event, Grade 3 TEAE severe or
medically significant but not immediately life-threatening events; hospitalization or prolongation of hospitalization
indicated; disabling; limiting self-care Activities of Daily Living, Grade 4 TEAE life-threatening consequences; urgent
intervention indicated. InterMune data on file
a Grade 3 erythema with desquamation
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CAPACITY studies, the most commonly
observed skin-related AEs were
photosensitivity reactions (observed in 12.2%
of pirfenidone-treated patients compared with
1.7% of placebo-treated patients) and rash
(occurring in 32.2% of pirfenidone-treated
compared with 11.5% of placebo-treated
patients). Events were mild to moderate
in severity (Table 2). Photosensitivity reaction
led to discontinuation in three (0.9%)
pirfenidone-treated patients and one (0.3%)
placebo-treated patient. Rash led to
discontinuation in five (1.4%)
pirfenidone-treated patients and no
placebo-treated patients [15]. An example of
photosensitivity on the exposed skin of a
pirfenidone-treated patient is shown in Fig. 2a.
The seasonal variation in frequency of skin
reactions in the CAPACITY studies suggests an
association with high-intensity sunlight
exposure (Fig. 1b). Laboratory studies have
suggested that the underlying mechanism of
pirfenidone in photosensitivity reactions is
likely to be phototoxic and related to the
drug’s ability to absorb both ultraviolet (UV) B
and UVA (Fig. 1c) [30]. Absorption of UV light
by pirfenidone in skin tissue could result in skin
lesions due to the generation of reactive oxygen
species and lipid peroxidation, as both occur
in vitro at physiologically relevant
concentrations [30]. Although no wavelength
dependency studies have been conducted in
humans, preclinical guinea pig findings support
the hypothesis that pirfenidone-induced skin
reactions are phototoxic, and therefore
proportional to light exposure and drug
concentration [31]. These animal studies also
demonstrate that the use of a sunscreen with a
high protection factor significantly reduces the
severity of skin reactions. Whether the
wavelength dependency extends into the
visible region in man is yet unknown.
Fig. 2 Photosensitivity in pirfenidone-treated patients.
a Patient 1: mild photosensitivity after 8 h driving. The patient
had been receiving treatment with pirfenidone for 7 days. The
patient presented with erythema localized to the more
photoexposed areas of the hands. He had previously followed
advice regarding photoprotection. On the day in question, he
used a broad-spectrum SPF50? sunscreen in the morning
before sun exposure, but did not repeat the application.
bPatient2:moderate photosensitivity after 14 days pirfenidone
treatment. The patient presented with erythema and peeling,
mainly on the hands and face. Patient had omitted to apply
sunscreen protection. c Patient 2: the same patient improved
following 7 days of topical treatment (silver sulfadiazine),
sunscreen protection, and pirfenidone dose reduction. The
patients and treating physicians provided permission for the use
of these images. SPF sun protection factor
382 Adv Ther (2014) 31:375–391
RECOMMENDATIONS FOR THE
PREVENTION AND MANAGEMENT
OF PIRFENIDONE-RELATED AES
Treatment management should be deployed in
centers with appropriate expertise and
experience in the management of IPF. The
recommended daily dose of pirfenidone in
Europe for adult patients with IPF is three
267 mg capsules three times a day with food
(preferably at the end rather than the beginning
of themeal) for a totalof2,403 mg/day [23].Upon
initiating treatment, the dose is titrated over a
14-day period to the recommended daily dose of
nine capsules (2,403 mg) per day: first week, one
capsule (267 mg) three times a day; second week,
two capsules (534 mg) three times a day; third
week onwards, full dose of three capsules
(801 mg) three times a day [23]. It is
recommended that pirfenidone is taken with
food, typically during or after a meal in order to
prevent drug-related AEs [23]. Generally, a
stepwise clinical approach as described in Fig. 3
can be adopted to manage pirfenidone-related
GI and skin-related AEs.
The following sections report
recommendations on additional measures that
may be adopted in daily practice for the
prevention and management of GI and
skin-related AEs, based on the summary of
product characteristics (SmPC) and
complemented by our opinion and
observations from clinical experience. It
should be noted that decisions regarding
treatment, particularly re-introduction
following discontinuation due to AEs, should
always be made in conjunction with the
patient, who should be made fully aware of
potential drug side-effects. Both parties should
consider the balance between quality of life and
efficacy benefits of continued treatment in
order make informed decisions on disease
management.
Gastrointestinal Adverse Events
In addition to current recommendations to take
pirfenidone during or after a meal [23], we
suggest further practical considerations in
patients experiencing tolerability challenges
from GI AEs, such as taking each of the three
capsules separately throughout the meal, rather
than simultaneously. If the meal consists of
several courses, each capsule could be taken
between courses. In support for this
recommendation, preclinical studies have
shown that splitting pirfenidone doses
partially alleviates pirfenidone’s inhibitory
effect on gastric motility in animal models
(InterMune data on file). This is further
supported by a real-world study in which
patients were encouraged to take pirfenidone
at the start, middle, and end of a meal to help
minimize side-effects [32].
To further improve pirfenidone’s tolerability,
we suggest that a longer initial dosing titration
scheme—for example, starting with one capsule
three times a day and titrating up to the full
dose (three capsules three times a day) over a
period of 4 weeks instead of 2 weeks—may be
Fig. 3 Stepwise approach to the prevention and
management of pirfenidone-related AEs. AE adverse event
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employed. This approach is currently under
investigation in a clinical setting
(Clincialtrials.gov #NCT01933334) [33].
Dose Reduction
If pirfenidone-related AEs are not tolerable, dose
reductions may be helpful, as the incidence of
GI and skin-related AEs with pirfenidone
treatment appear to be dose dependent as
shown in animal models [34]. Depending on
the nature and severity of the AE, we suggest
that the pirfenidone dose may be reduced to 1
or 2 capsules (267–534 mg), 2–3 times a day
with food, with re-escalation to the
recommended daily dose as tolerated. In
support of this suggestion, preclinical studies
have shown that pirfenidone reduces gastric
emptying and small intestinal transit rates in a
dose-dependent manner [29].
If dose reduction is required, we suggest to
first reduce the dose corresponding to the time
of the day when AEs are the most pronounced.
For example, if nausea is experienced in the
morning, delaying or reducing the morning
dose to one or two capsules, may help mitigate
GI symptoms. Dietary and cultural habits
should be taken into account when advising
patients.
Temporary Dose Interruption and
Re-challenging
If AEs still persist despite dose reduction,
temporary treatment discontinuation until
symptoms become tolerable (typically
1–2 weeks) should be considered. Once
symptoms have resolved or become tolerable,
pirfenidone may be re-introduced. In some
treatment centers, a slower re-escalation
scheme (i.e., longer than the usual 2 weeks)
after temporary treatment interruption has
been employed.
Prokinetic Medication
Use of prokinetic agents such as domperidone,
mosapride, and metoclopramide may help
mitigate treatment-related GI AEs [35]. Indeed,
animal studies have shown that prokinetic
agents such as mosapride reduce pirfenidone’s
inhibitory effects on gastric emptying and
intestinal transit rates [29]. Metoclopramide
(for a maximum of 5 days) and domperidone
(no restriction on length of use) are both dosed
at 10 mg three times a day. Use of proton pump
inhibitors may also be helpful for managing GI
side-effects in pirfenidone-treated patients with
IPF [36].
Skin-Related Adverse Events
Preclinical studies have shown that
pirfenidone-induced photosensitivity reactions
reflect the drug’s pharmacokinetic profile and
are proportional to sunlight exposure,
decreasing with the use of higher sun
protection factor (SPF) sunscreens. Therefore,
sun exposure should be avoided for a few hours
following pirfenidone intake, to allow the
drug’s plasma concentration to decrease.
Animal studies have suggested that the extent
of phototoxicity is linked to pirfenidone’s
plasma concentration (InterMune data on file).
The standard approach for preventing and
managing skin AEs as recommended in the
SmPC [23] includes avoiding exposure to direct
sunlight (including sunlamps), use of sunscreen
active against both UVA and UVB, use of
protective clothing, and avoidance of other
medicinal products known to cause
photosensitivity. We expand on this guidance
by suggesting: behavioral avoidance of indirect
(in addition to direct) sunlight, as well
as intense artificial light sources (such as
energy-saving fluorescent lamps); wearing of
384 Adv Ther (2014) 31:375–391
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thick-weave clothing, use of a broad-brimmed
hat, and, when necessary, gloves.
To further illustrate the above guidance of
the SmPC, Table 3 details our expert
recommendations to prevent skin
photosensitivity reactions, highlighting the
importance of behavioral changes and
protection through appropriate clothing and
thorough sunscreen application.
Dose Reduction
In cases of mild to moderate photosensitivity
reaction or rash (i.e., when the vast majority of
burn is superficial—painful erythema and
scaling may be present on exposed areas, but
with no edema, exudation, or blistering) that
does not spontaneously resolve, the dose may
be reduced to one capsule (267 mg) three times
a day for 7 days, or until symptom resolution.
Symptoms are considered to be resolved once
the redness and scaling have disappeared.
Temporary Dose Interruption and
Re-challenging
If a rash persists for more than 7 days despite
pirfenidone dose reduction, therapy should be
discontinued for approximately 15 days. Upon
resolution, pirfenidone may be re-introduced
and re-escalated to the recommended daily
dose, or as tolerated, in the same manner as
the initial regime, or using the slower
re-escalation regime previously described (i.e.,
extended over 4 weeks as opposed to 2 weeks).
Patients experiencing a severe
photosensitivity event (erythema and edema
with exudation, erosions, blistering, cracked or
scarred skin, possible dehydration) of
sun-exposed skin (i.e., a non-allergic reaction),
should be instructed to seek medical advice on
dose adjustments and temporary
discontinuation, until the skin reaction
normalizes. In our collective clinicalT
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experience, use of topical treatments for burns
(e.g., silver sulfadiazine or potent steroids)
immediately after the appearance of skin
lesions may help attenuate reactions and
improve associated symptoms. An example of
a patient with moderate sensitivity treated with
topical emollients and a reduction in
pirfenidone dose is shown in Fig. 2b, c.
After the skin reaction has cleared,
pirfenidone may be re-introduced with the
slower stepwise re-escalation scheme. If
exposure to sunlight at mid-day is
unavoidable, the pirfenidone dose at
lunchtime could be reduced.
It should be noted that a significant number
of skin-related AEs experienced with
pirfenidone are associated with unprotected
sun exposure. Rashes that appear allergic in
nature (urticarial or occurring on parts of the
body that are not exposed to sunlight) are
uncommon. If such a rash occurs, however,
pirfenidone should be permanently
discontinued, and the use of anti-histamines
and oral prednisone should be considered.
Correct diagnosis of an allergic rash is very
important, as these patients should not be
re-challenged with pirfenidone.
In cases of photosensitivity, the decision
about re-challenging following treatment
interruption must be made according to
clinical judgment based on the type and
severity of the reaction; dermatological advice
can be helpful. Dose interruption can be
avoided if enough emphasis is placed on
prevention methods, as described in Table 3.
Patients should be encouraged to take
photographs of any skin changes to aid
diagnostic evaluation, particularly if
uncertainty exists as to whether a rash has a
phototoxic- or an allergic-type mechanism.
Improving Patient Education
Patient education is a central part of the
management of skin AEs and should include
communication with a patient’s spouse or carer.
Accordingly, physicians, nurses, and
pharmacists play an important role in the
dissemination of patient educational materials
(such as the patient information leaflet [37])
and in emphasizing preventive measures (e.g.,
behavioral, clothing, and sun protective barrier
use). Ideally, physicians and nurses should
dedicate adequate time to educate patients
with respect to preventive measures and
behavioral changes.
As previously described, the importance of
generous and frequent re-application of a high
SPF and high UVA (extending into the visible
region) type of sunscreen should be
emphasized. The use of existing supporting
patient educational materials [37] and simple
educational tools is highly recommended. Some
centers have dedicated nurses and/or specific
home-care programs that play an important
role in this area. Patients should be made aware
that although dense cloud, thick clothing, and
glass may offer some protection against UV
exposure, UVA rays may penetrate such barriers,
which is important with respect to driving.
Prescribing or recommending a broad-spectrum
sunscreen at the same time as pirfenidone may
emphasize the importance of sun protection.
In terms of AE management, the physician
plays a central role by communicating
preventive measures and existing educational
tools to the patient. During patient assessment,
the physician has the opportunity to educate
and provide the best advice to the patient by
considering clinical history (skin phototype and
previous history of photosensitive skin disease
such as lupus erythematosus, polymorphic light
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eruption, etc.), possible outdoor occupations
(e.g., laborer, farmer) or hobbies/sport (e.g.,
golfing, sailing), concomitant treatment with
other photosensitizing drugs (e.g., tetracycline
antibiotics), and the patient’s mental health state
(which can affect motivation and adherence). For
patients who present with photosensitivity
despite significant photoprotection, it is
important to consider the possibility of vitamin
D deficiency. A vitamin D plasma assay should be
considered with administration of oral vitamin D
as appropriate.
The outcomes of efficient patient
communication are highlighted in a real-world
pirfenidone study of 40 patients with IPF [32].
During the first 6 months of this study six
patients (15%) discontinued treatment due to
AEs. In the latter 10 months, however, there were
no discontinuations. The authors of this study
[32] attribute this to a number of factors,
including a monthly specialist nurse review (for
the first 3 months of treatment) to assess and
reinforce AE avoidance measures. Patients were
also given a contact number and encouraged to
speak with a specialist nurse if they experienced
any AEs; this ensured that appropriate measures
such as dose reduction, temporary
discontinuation, and/or additional treatment of
side-effects could be enforced without delay in
order to rapidly alleviate AEs [32]. This real-world
study suggests that simple patient education and
communication measures can substantially
increase treatment adherence and compliance,
which enables patients with IPF to benefit from
the decreased disease progression observed with
continued pirfenidone treatment.
CONCLUSION
Data from clinical trials show the clinically
meaningful benefit and favorable safety profile
of pirfenidone. While dose reduction can
improve AE tolerability by mitigating AE
occurrence/severity, better management of AEs
will lead to optimized care and allow patients to
benefit from the potential effectiveness of
pirfenidone. To prevent and manage GI and
skin-related AEs more effectively, further
research is required to understand the effect of
pirfenidone on gastric motility and
photosensitivity reactions. Our opinions
regarding the prevention and management of
pirfenidone-related AEs in clinical practice are
summarized in Table 3. These should be
regarded as a complement to the available and
published information on pirfenidone.
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